imo, I have to partially agree with quotsa. I feel there is dilution occurring as we speak and the stock will continue to spiral right into "Le Toilet" (pronounced Twa-Let) ;)~
imo, after the r/s, it would make sense for Maza to wait for the following Phase 1 trial results for OX1 in Nov 2014 before commencing with his wonderful dilution. If OX1 migrates to Phase 2, do we receive a milestone payment? Obviously, it depends on the contract details with Shire (Viropharma). That's a good question for Maza. Anything North of $5M and ILNS will be in pretty good shape. They will have another update for Ponz in Jan 2015.
Maza has got to move Tau & Conjumab forward. You become a more attractive acquisition target when you have drugs in clinical trials and perhaps good results for OX1 with the possible Orphan Drug Status.
I don't think Maza will dilute right away after r/s. However, if we receive no milestone payment for OX1 Phase 1 - 2 migration, and he does not secure additional financing, oh well, I think the correct term is "dissipate like a fart in the wind".
Cheers
News 
Market Data 
Discover 
